An Open-Label, Uncontrolled, Single Center, Phase I Trial to Assess the Safety of VM206RY in Subjects With Expression of Her2 in Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 27 Jan 2015
Price : $35 *
At a glance
- Drugs VM 206 (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 22 Oct 2013 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
- 18 Oct 2013 Planned End Date (Nov 2013) added as reported by ClinicalTrials.gov.